We have performed differential display comparing gene expression from cell lines derived from human colorectal tumors. The cell lines were selected for study based on their ability to form metastases following injection into athymic mice. One gene which was expressed exclusively by the metastatic lines was identified as human acylphosphatase (e.c. 3.6.1.7, acylphosphate phosphohydrolase). The expression of this gene was confirmed by RT-PCR using gene-specific primers. This gene product catalyzes the hydrolysis of phosphorylated intermediates of Na⍣/K(⍣)-ATPase and of Ca(2⍣)-ATPases of mammalian cells. Changes in the activity of the Na⍣/K(⍣)-ATPase pump, regulated by acylphosphatase, have been previously reported in chemically-induced colonic tumors. The differential expression of this gene in the human metastatic colorectal lines suggests it may be involved in the metastatic phenotype.
Colon cancer results in nearly 50 000 deaths per year in the United States, with most of the deaths attributable to liver metastases (1) . Though much work has been done investigating and identifying the sequential genetic mutations that result in the appearance of colon carcinomas (2) , there has been only one report identifying the differential expression of a gene linked to the metastatic phenotype of patients with colorectal cancer (3) .
To further delineate genes associated with the metastatic phenotype, we have established 11 cell lines derived from human colorectal tumors of varying histologic stage (T.J.Farrell, D.L.Ornstein, M.P.Vincenti, O.S.Pettengill, C.E. Brinckerhoff, C.C.Cate, D.E.Longnecker and K.Cohn, submitted). Eight cell lines were injected into athymic mice to assay their metastatic potential in this well defined in vivo model. Two cell lines formed primary tumors and liver metastases, two cell lines formed only primary tumors, and four cell lines showed no primary or metastatic tumor formation. The expression levels of tissue inhibitor of metalloproteinase-2 (TIMP-2*), gelatinase A, and membrane type matrix metalloproteinase-1 (MTMMP-1) genes, already shown to be associated with metastases (4), were then studied by RT-PCR (D.L.Ornstein, J.Macnab and K.Cohn, submitted). To further identify genes responsible for the metastatic phenotype, differential display was performed using RNA from the cell lines exhibiting differential metastatic behavior. Seventeen human cDNAs were cloned, sequenced, and then identified using the *Abbreviations: TIMP-2, tissue inhibitor of metalloproteinase-2; MTMMP-1, membrane type matrix metalloproteinase-1.
NIH database. One cDNA encoded acylphosphatase and was shown to be differentially expressed. It is noteworthy that the activity of this enzyme has been previously shown to be altered during the induction of experimental colon cancer (5) .
The colorectal cell lines were maintained in Ham's Nutrient Medium-F12/Dulbecco's Modified Eagle's Medium (Sigma, St Louis, MO), supplemented with 10% heat inactivated fetal bovine serum (Sterile Systems, Logan, UT), 2 units/ml penicillin, 2 µg/ml streptomycin, and 4 µg/ml amphotericin B. Cell cultures were incubated in 5% CO 2 at 37°C; the medium was changed every 3-5 days as needed. Six to eight-week-old athymic BALB/c mice obtained from NCI-Frederick Cancer Facility were maintained in a laminar-flow environment in an AAALAC accredited facility. Animals were anesthetized by methoxyflurane cone in a class II biosafety hood. Each animal was injected with 2-4 million cells, as determined by hemocytometer; the cells were shown to be viable by trypan blue exclusion. The injection volume was 0.2 ml in phosphate buffered saline. Each cell line was injected into the hind limb (3 animals) or into the splenic capsule (3 animals) (6). Mice were killed when hind-limb tumors measured 1-2 cm in diameter or when liver metastases were palpable. Non-tumor bearing animals were killed 4 months after injection to confirm absence of primary tumor and metastases. After being killed, tumor volume was recorded and specimens were snap-frozen in liquid nitrogen and cryopreserved for subsequent RNA and DNA extraction; an additional specimen was placed into paraformaldehyde for subsequent in situ hybridization. Finally, representative cryopreserved tumors were embedded in OCT medium (Tissue-Tek, Miles Inc., Elkhart, IN), were cut into 4 µm sections, and stained with hematoxylin and eosin for histologic confirmation of tumor type (adenocarcinoma).
Total RNA was harvested from the human colorectal cancer cell lines using RNA STAT-60 (Tel Test B, Friendswood, TX) according to manufacturer's instructions and precipitated with 2.5 volumes of 100% ethanol. The amount and purity of RNA was determined by the ratio of absorption at 260/280 nm. The RNA was stored until needed at -70°C in RNAse-free water. One microgram of total RNA was used to prepare first strand cDNA for PCR according to the manufacturer's instructions (GenHunter, Nashville, TN). The cDNA was amplified by PCR using a random primer in combination with the primer used to create the initial first strand of cDNA, following manufacturer's instructions. The one exception was that the radionucleotide used to label the resulting cDNAs was alpha [ 33 P]ATP (2000 Curies/mmol, New England Nuclear, Boston, MA) because it gave better resolution on the differential display gels than 32 P and produced results in less time than 35 S. PCR was carried out for 40 cycles of denaturation at 94°C for 15 s, annealing at 40°C for 30 s, and extension at 72°C for 2 min followed by a final extension at 72°C for 10 min in a GenAmp PCR System 9600 (Perkin-Elmer, Roche Molecular Systems, Branchburg, NJ). The PCR products were resolved by electrophoresis on a 6% denaturing polyacrylamide gel and Bands of interest were excised from the gel, and the c DNA was recovered by boiling for 10 min in 100 µl water. An aliquot was reamplified using the same conditions and primers. The resulting product was run on a 1% agarose gel for quantitation, and 25 ng ligated into the pCR II vector (Invitrogen, San Diego, CA) according to manufacturer's instructions. Sequencing of the cDNA insert was performed with an Applied Biosystems Model 373A DNA Sequencing System (San Diego, CA) using their Prism Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit. Sequence data was compared to the GenBank and EMBL DNA databases using the BLAST search program available through the National Institutes of Health. Table I shows injection of cell lines #43 and #22 resulted in primary tumors of 0.5-1.0 cm in the thighs in animals that were injected in the hind limb. Animals that received intrasplenic injections of the same cell lines formed 0.5-1.0 cm diameter tumors at the site of injection and multiple liver tumors, 0.5-2.5 cm in diameter, occupying 90-95% of the liver at autopsy. Cell lines #51 and #13 produced primary tumors in the thigh measuring 1-2 cm 9 weeks after hind limb injection, but no liver metastases or other tumor deposits were seen at autopsy 13 weeks after intra-splenic injection. Cell lines #17, #13m, #46, and #35 produced neither primary tumors after hind limb injection nor liver metastases after intrasplenic injection when killed at 16 weeks. No distant metastases were seen at autopsy in any animal which underwent hind limb injection, consistent with findings reported by other investigators (7) . Comparison of sequence data derived from differential display fragments with the database maintained at the NIH using the BLAST algorithm showed identity with 17 human EST fragments (expressed sequence tags). The identification of the differential display fragments with previously cloned and sequenced human cDNAs helped to eliminate artifactual fragments, and consequently helped identify differentially displayed fragments that represented actual human cDNAs.
Of the 17 cDNA fragments cloned and sequenced, eight showed homology to full-length cDNAs commercially available (GSI, St Louis, MO). One clone was obtained whose expression appeared only in the two metastatic lines. The differential expression was subsequently confirmed by the use of sequencespecific primers in a RT-PCR reaction (Figure 1 ). This clone contained a full-length cDNA insert of 412 bp, while its homologous differential display band contained only 138 bp. The fulllength cDNA was identified as human acylphosphatase (e.c. 3.6.1.7, acylphosphate phosphohydrolase), which catalyzes the hydrolysis of phosphorylated intermediates of Naϩ/K(ϩ)- ATPase and of Ca(2ϩ)-ATPases of mammalian cells (8, 9) . This enzyme regulates cation transport (10) . Acylphosphatase has been shown to block ras-p21 induced maturation of ooctyes in Xenopus laevis (11) , suggesting that acylphosphatase influences signal transduction in mammalian cells. Finally, changes in the activity of the Naϩ/Kϩ-ATPase pump, which is regulated by acylphosphatase, have been reported in 1,2 dimethylhydrazineinduced colonic tumors (5) . Consequently, we have cloned this cDNA into a mammalian expression vector, and transfection studies are underway to determine if the expression of this gene in nonmetastatic human colorectal cell lines alters their metastatic phenotype.
The use of differential display to identify genes involved in human cancers has been reported by a number of investigators in recent years (12) (13) (14) (15) (16) . Differential display facilitated the isolation and cloning of a cDNA fragment expressed only in the normal cell line. This fragment was then used to isolate the full-length cDNA, and thus to identify a putative tumor supressor gene. In another report using differential display technology, gene expression was compared in metastatic and non-metastatic gastric cancer cell lines (17) . Five previously unknown cDNAs were identified and one showed much higher expression in the metastatic cell line. Yeatman et al. reported (3) the identification of a differentially expressed gene that appeared to be associated with liver metastasis. Thus, differential display is proving to be a powerful tool to isolate novel cDNAs involved in metastasis. Since metastasis is a complex phenomenon, genes may exist whose role remains to be elucidated. Differential display offers a state-of-the-art technique which facilitates investigation of gene expression in metastatic colorectal cancer.
